![Eric Soyer](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Eric Soyer
Director of Finance/CFO at PHAXIAM THERAPEUTICS S.A.
Profile
Eric Soyer is currently the Deputy CEO, Chief Financial & Operating Officer at PHAXIAM Therapeutics SA since 2023.
He is also currently serving as the Chief Financial Officer at Maat Pharma SA since 2024.
Previously, Mr. Soyer worked as the Chief Financial Officer & Managing Director at EDAP TMS SA from 2012 to 2015.
He also held positions as the Managing Director & Chief Financial Officer at April SAS, Director, Chief Operating & Financial Officer at ERYTech Pharma SA, and Managing Director at EDAP TMS France SAS. Additionally, he served as the Chief Financial Officer at Medica SA from 2005 to 2006 and as the Controller & Cost Accountant at Compagnie Générale des Établissements Michelin SCA from 1991 to 1999.
He also worked as a Financial Controller & Cost Accountant at Michelin Group.
Mr. Soyer's education includes an MBA from the University of Kansas in 1989, an MBA from École des Hautes Études Commerciales de Paris in 2004, and an undergraduate degree from Ecole Supérieure de Commerce de Clermont-Ferrand in 1989.
Latest news about Eric Soyer
Eric Soyer active positions
| Companies | Position | Start |
|---|---|---|
| PHAXIAM THERAPEUTICS S.A. | Director of Finance/CFO | 22/06/2023 |
| MAAT PHARMA | Director of Finance/CFO | 31/10/2024 |
Former positions of Eric Soyer
| Companies | Position | End |
|---|---|---|
| EDAP TMS S.A. | Director of Finance/CFO | 13/07/2015 |
| MEDICA | Director of Finance/CFO | 31/10/2006 |
| MICHELIN (CGDE) | Comptroller/Controller/Auditor | 30/04/1999 |
Michelin Group
 Michelin Group Manufactures tires | Comptroller/Controller/Auditor | - |
ERYTech Pharma SA
 ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology Develops medicinal products for orphan oncology and rare diseases | Director of Finance/CFO | - |
Training of Eric Soyer
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 12 |
|---|---|
EDAP TMS SA
 EDAP TMS SA Medical SpecialtiesHealth Technology Develops, produces and markets minimally invasive medical devices for urological diseases | Health Technology |
Medica SA
 Medica SA Hospital/Nursing ManagementHealth Services Operates as a holding company with interests in assisted living retirement homes | Health Services |
Compagnie Générale des Établissements Michelin SCA
 Compagnie Générale des Établissements Michelin SCA Automotive AftermarketConsumer Durables Manufactures tires and rubber products | Consumer Durables |
April SAS
 April SAS Insurance Brokers/ServicesFinance Provides insurance brokerage services | Finance |
University of Kansas
 University of Kansas Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
École des Hautes Études Commerciales de Paris
 École des Hautes Études Commerciales de Paris Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ecole Supérieure de Commerce de Clermont-Ferrand
 Ecole Supérieure de Commerce de Clermont-Ferrand Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ERYTech Pharma SA
ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology Develops medicinal products for orphan oncology and rare diseases | Health Technology |
EDAP TMS France SAS
 EDAP TMS France SAS Medical SpecialtiesHealth Technology Manufactures medical, surgical and dental equipment | Health Technology |
Maat Pharma SA
 Maat Pharma SA Operates as a clinical stage company which develops and commercializes patient-microbiome symbiosis to improve survival outcomes in oncology | |
Michelin Group
Michelin Group Manufactures tires | |
PHAXIAM Therapeutics SA
 PHAXIAM Therapeutics SA Operates as a biopharmaceutical company that develops innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases |
- Stock Market
- Insiders
- Eric Soyer
